MBX Biosciences
Update in progressMBX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MBX Biosciences is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders. Its lead candidate, Canvuparatide (MBX 2109), is a PTH peptide prodrug in Phase 3 for chronic hypoparathyroidism. Imapextide (MBX 1416) is a long-acting GLP-1 receptor antagonist in Phase 2 for post-bariatric hypoglycemia. MBX 4291 targets obesity in IND-enabling studies. Founded 2018, Carmel, Indiana.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!